DNTH Company Profile and Key Details

DNTH has shown sold momentum, gaining 19.12% over the past week and 30.72% over the past quarter, though year-to-date performance is up 13.08%. Short-term trend indicators are bearishly aligned (SMA20 4.89%, SMA50 14.76%, SMA200 62.2%). The stock’s 14-day RSI is 59.62 (neutral), while the ATR of 3.05 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.63% below its high and over 297.38% above its low. Average 10-day trading volume of 476.83 thousand shares is below the 3-month average of 1.02 million, indicating normal recent market interest.

Dianthus Therapeutics, Inc. has 55.93 million shares outstanding. The public float is 55.50 million shares, elevated short interest at 17.60% of float. This equals 8.38 million shares. The short ratio is 8.49 days. Institutional investors hold 121.39% of the float. Insiders own 0.13%. Fairmount Funds Management LLC holds 1.93 million shares, Garcia Marino has 65.29 thousand shares and Randhawa Simrat has 4.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 158.11 thousand shares across 18 transactions.

Dianthus Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$2.69. This means the shares are trading below this model’s fair value.

Dianthus Therapeutics, Inc. generated EPS of -$3.49 over the past year. Five-year average earnings growth is 40.14%. Wall Street analysts project EPS growth of -19.47% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 16 Strong Buy ratings, 13 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $200.00 to $40.00. The high target offers 85.44% upside. The low target suggests -62.91% downside. The mean target is $95.72. This offers -11.25% upside. Dianthus Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 04, 2026, missed forecasts by 6.35%. The prior quarter beat by -20.7%. Over the last six quarters, Apple has recorded several small beats. These include -4.65% in May 12, 2025.

Dianthus Therapeutics, Inc. trades at a P/E ratio of -831.6, slightly below the S&P 500 average, with a price-to-sales ratio of 3175.92 and a price-to-book ratio of 5.17 trading at moderately above to book value. The P/FCF stands at -38.83, also below market averages.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) closed at $108.10 USD, gaining $0.25 (0.23%) from the previous close of $107.85. The stock is currently mid-range between its 52-week high and low $24.49 and $117.88. With a market capitalization of about $6.05 billion, Dianthus Therapeutics, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.08). Key stats such as the average daily volume over the past year has been around 1.03 million shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Dianthus Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marino Garcia, the company employs approximately 92 people and listed since June 21, 2018. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares are up 13.08% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Dianthus Therapeutics, Inc. trading at a premium to the broader market with a P/E of -831.6. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $86.78, suggesting -19.54% downside. Our AI forecast model points to short-term weakness (-5.56% over two weeks), a medium-term fall (-30.73% over three months), and a longer-term gain (15.71% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Dianthus Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -5.56%, with price expected at $101.85 by September 17, 2026, within a range of $98.73 to $105.04 3-Month Outlook: Projected fall of -30.73%, reaching $74.71 by December 02, 2026, with a range of $71.32 to $78.42. 1-Year Outlook: Projected gain of 15.71%, with price at $124.79 by September 03, 2027, within a range of $118.56 to $131.27.